Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05130736
Other study ID # 514/21
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2021
Est. completion date December 31, 2022

Study information

Verified date November 2021
Source Poznan University of Medical Sciences
Contact Katarzyna Hojan, MD, PhD
Phone +48618546573
Email khojan@ump.edu.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to compare the effectiveness of two models of rehabilitation: - traditional neurological rehabilitation, and - neurological rehabilitation combined with a rehabilitation robot (Luna by EGZOTech). An additional goal is to test the qualitative diagnostic reference using the surface electromyogram of the Luna robot (certified as a Medical Device) for functional diagnostics based on standardized clinical tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients discharged from Intensive Care Units after undergone ventilator therapy due to COVID-19 Exclusion Criteria: - active medical condition (infections; tumors; rheumatological, metabolic, endocrine, autoimmunological, cardiovascular diseases) - bipolar disorder - dementia - nutritional disorders - addiction to alcohol or psychoactive substances - severe obesity - overtraining

Study Design


Intervention

Device:
Robot rehabilitation
Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation

Locations

Country Name City State
Poland Poznan University of Medical Sciences Poznan

Sponsors (3)

Lead Sponsor Collaborator
Poznan University of Medical Sciences EGZOTech sp. z o.o., Szpital Wojewódzki w Poznaniu

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in muscle fatigue assessment Raw robot measurement data (isometric contraction of the muscle for 60 s - biceps, quadriceps) Baseline, after 3 and after 8 weeks
Primary Change in isokinetic muscle force Raw robot measurement data (5 repetitions during measurement with LUNA) Baseline, after 3 and after 8 weeks
Secondary Change in functional physical ability 1 Functional Independence Measure Baseline, after 3 and after 8 weeks
Secondary Change in functional physical ability 2 Barthel Index Baseline, after 3 and after 8 weeks
Secondary Change in functional physical ability 3 Berg Balance Test Baseline, after 3 and after 8 weeks
Secondary Change in functional physical ability 4 Short Physical Performance Battery Baseline, after 3 and after 8 weeks
Secondary Change in cognitive ability 1 Addenbrooke's Cognitive Examination (ACE-III) Baseline, after 3 and after 8 weeks
Secondary Change in cognitive ability 2 Montreal Cognitive Assessment Baseline, after 3 and after 8 weeks
Secondary Change in the quality of life WHOQOL Baseline, after 3 and after 8 weeks
Secondary Change in depressive symptoms Beck's Depression Inventory Baseline, after 3 and after 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05430152 - Low-dose Naltrexone for Post-COVID Fatigue Syndrome Phase 2
Recruiting NCT04705831 - Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection Phase 4